Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study

Anja S Lindman, M B Veierød, A Tverdal, J I Pedersen, R Selmer, Anja S Lindman, M B Veierød, A Tverdal, J I Pedersen, R Selmer

Abstract

The association between nonfasting triglycerides and cardiovascular disease (CVD) has recently been actualized. The aim of the present study was to investigate nonfasting triglycerides as a predictor of CVD mortality in men and women. A total of 86,261 participants in the Norwegian Counties Study 1974-2007, initially aged 20-50 years and free of CVD were included. We estimated hazard ratios (HRs) for deaths from CVD, ischemic heart disease (IHD), stroke and all causes by level of nonfasting triglycerides. Mean follow-up was 27.0 years. A total of 9,528 men died (3,620 from CVD, 2,408 IHD, 543 stroke), and totally 5,267 women died (1,296 CVD, 626 IHD, 360 stroke). After adjustment for CVD risk factors other than HDL-cholesterol, the HRs (95% CI) per 1 mmol/l increase in nonfasting triglycerides were 1.16 (1.13-1.20), 1.20 (1.14-1.27), 1.26 (1.19-1.34) and 1.09 (0.96-1.23) for all cause mortality, CVD, IHD, and stroke mortality in women. Corresponding figures in men were 1.03 (1.01-1.04), 1.03 (1.00-1.05), 1.03 (1.00-1.06) and 0.99 (0.92-1.07). In a subsample where HDL-cholesterol was measured (n = 40,144), the association between CVD mortality and triglycerides observed in women disappeared after adjustment for HDL-cholesterol. In a model including the Framingham CHD risk score the effect of triglycerides disappeared in both men and women. In conclusion, nonfasting triglycerides were associated with increased risk of CVD death for both women and men. Adjustment for major cardiovascular risk factors, however, attenuated the effect. Nonfasting triglycerides added no predictive information on CVD mortality beyond the Framingham CHD risk score in men and women.

Figures

Fig. 1
Fig. 1
Flow chart illustrating how study samples were obtained from the three screenings. *Exclusions: Participants reporting a history of myocardial infarction, angina, stroke, diabetes, use of nitroglycerine or blood pressure reducing drugs, outside age range, extreme/missing triglyceride values or incomplete data on observation time

References

    1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–219. doi: 10.1097/00043798-199604000-00014.
    1. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease—10,158 incident cases among 2,62,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–458. doi: 10.1161/CIRCULATIONAHA.106.637793.
    1. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2678–2686. doi: 10.1161/01.CIR.0000145542.24347.18.
    1. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2–14.
    1. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473–485.
    1. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem. 2005;12:1931–1945. doi: 10.2174/0929867054546609.
    1. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309–316. doi: 10.1001/jama.298.3.309.
    1. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308. doi: 10.1001/jama.298.3.299.
    1. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300:2142–2152. doi: 10.1001/jama.2008.621.
    1. Bravo E, Napolitano M. Mechanisms involved in chylomicron remnant lipid uptake by macrophages. Biochem Soc Trans. 2007;35:459–463. doi: 10.1042/BST0350459.
    1. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 1993;307:1318–1322. doi: 10.1136/bmj.307.6915.1318.
    1. Tverdal A, Foss OP, Leren P, Holme I, Lundlarsen PG, Bjartveit K. Serum triglycerides as an independent risk factor for death from coronary heart-disease in middle-aged Norwegian men. Am J Epidemiol. 1989;129:458–465.
    1. The cardiovascular surveys in Finnmark, Sogn og Fjordane and Oppland. 1974–78, 1977–83 and 1985–88. . Accessed 21 Dec 2009.
    1. Bjartveit K, Foss OP, Gjervig T, Lund-Larsen PG. The cardiovascular disease study in Norwegian counties. Background and organization. Acta Med Scand Suppl. 1979;634:1–70.
    1. Bjartveit K, Foss OP, Gjervig T. The cardiovascular disease study in Norwegian counties. Results from first screening. Acta Med Scand Suppl. 1983;675:1–184.
    1. National Health Screening Service, Health Surveys of Finnmark, Sogn og Fjordane, and Oppland counties, Ullevål Hospital, Central laboratory, Oslo. The cardiovascular disease study in Norwegian counties. Results from second screening. Oslo: National Health Screening Service; 1988.
    1. Stensvold I, Urdal P, Thürmer H, Tverdal A, Lund-Larsen PG, Foss OP. High-density-lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women. Eur Heart J. 1992;13:1155–1163.
    1. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–298. doi: 10.1016/0002-8703(91)90861-B.
    1. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150:341–353.
    1. Ferns G, Keti V, Griffin B. Investigation and management of hypertriglyceridaemia. J Clin Pathol. 2008;61:1174–1183. doi: 10.1136/jcp.2008.055756.
    1. Stalenhoef AF, de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol. 2008;19:355–361. doi: 10.1097/MOL.0b013e328304b63c.
    1. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002;106:2137–2142. doi: 10.1161/01.CIR.0000035280.64322.31.
    1. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832–1844. doi: 10.1161/CIRCULATIONAHA.106.676890.
    1. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–1639. doi: 10.1016/S0140-6736(10)60545-4.
    1. Austin MA. Triacylglycerol and coronary heart disease. Proc Nutr Soc. 1997;56:667–670. doi: 10.1079/PNS19970066.
    1. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000. doi: 10.1001/jama.2009.1619.
    1. Vollset SE, Selmer R, Tverdal A, Gjessing H. Mortality from smoking in Norway. Norwegian Institute of Public Health; 2006. (ISBN: 82-8082-163-5, electronic version).
    1. Graff-Iversen S, Hammar N, Thelle DS, Tonstad S. Hormone therapy and mortality during a 14-year follow-up of 14,324 Norwegian women. J Intern Med. 2004;256:437–445. doi: 10.1111/j.1365-2796.2004.01396.x.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj